RxDoctor Payments Data

Robert Flurry, MD

Family Medicine · Pensacola, FLNPI 1396745147

Payments from drug & device makers

$12,413in general payments, 2019–2025

Across 859 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$739
  • GSK$653
  • Boehringer Ingelheim$590
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$12,13398%
  • Education$2792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,413 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$361,548
Medicare patients
569
Services billed
7,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide186$199,807
OzempicSemaglutide182$186,354
EliquisApixaban161$140,012
JardianceEmpagliflozin134$133,285
FarxigaDapagliflozin Propanediol97$101,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$93,417
NuplazidPimavanserin Tartrate14$67,636
TrulicityDulaglutide45$56,698
XareltoRivaroxaban48$54,591
LinzessLinaclotide49$47,447
MyrbetriqMirabegron58$44,717
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$24,130
InvokanaCanagliflozin24$22,028
NuedextaDextromethorphan Hbr/Quinidine12$19,303
VraylarCariprazine Hcl12$17,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$558$256,505231 claims
Novo NordiskOzempic$1,858$186,354182 claims
PfizerEliquis, Premarin$1,295$148,572187 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arexvy$653$136,880243 claims
Boehringer IngelheimJardiance$590$133,285134 claims
AstraZenecaFarxiga, Breztri Aerosphere$739$109,581110 claims
Johnson & JohnsonXarelto, Invokana$215$76,61972 claims
AbbVieLinzess, Vraylar, Synthroid$1,461$71,538155 claims
Astellas Pharma US IncMyrbetriq$346$44,71758 claims
Avanir Pharmaceuticals, Inc.Nuedexta$39$19,30312 claims
Sumitomo Pharma America, Inc.Gemtesa$406$13,53018 claims
MerckJanuvia$59$12,10612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →